Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNSH.L Regulatory News (NSH)

  • There is currently no data for NSH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preliminary Results

12 Mar 2021 07:00

RNS Number : 0240S
Norish PLC
12 March 2021
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

Chairman's Statement

 

Norish plc (AIM: NSH), is pleased to announce its results for the year ended 31 December 2020.

 

Notwithstanding Covid 19 and Brexit associated disruption, our business performed very well in the period under review.

· The cold store division saw an EBITDA decline of only 2%, despite greatly reduced pallet intakes and slower stock turn.

· Our dairy division continues to execute to plan, commercialising A2 protein milk products from our own unique milk source.

· The protein sourcing business continued to be profitable in the period under review.

· Balance sheet further improved, with net debt reduced.

· Strategic review of Cold Store Assets initiated.

 

Group Financial Highlights

· Group revenue reduced by 2% to £33.4m (2019: £34.1m)

· Profit before tax reduced by 14% to £1.98m (2019: £2.31m)

· Diluted adjusted Eps decreased by 21% to 5.02p (2019: 6.33p)

· Effective tax rates increased to 23.7% (2019: 17.8%)

· Operating margins decreased by 90 bps to 6.9% (2019: 7.8%)

· Dividend proposed at 2.0 €cent per share (2019: proposed not paid of 1.90 €cent per share)

· Net debt was reduced from Stg£9.7m at start of year to Stg£8.7m at year end.

· Interest cover was 7.3 times (2019: 7.7 times)

 

Diluted adjusted EPS is calculated using profit for the financial year from continuing operations as the measure of earnings. Financial information above, including comparative information, is from continuing operations only.

 

Divisional Highlights

 

£'m

Cold Stores

Sourcing

Dairy

 

2020

2019

% Growth

2020

2019

% Growth

2020

2019

% Growth

Revenue

14.6

15.1

(3.3%)

17.8

18.2

(2.2%)

1.0

0.9

11%

EBITDA

4.6

4.7

(2.1%)

0.3

0.4

(25%)

0.0

0.0

0%

Operating Profit

3.0

3.3

(9.1%)

0.3

0.4

(25%)

(0.1)

(0.1)

0%

Operating Margin

20.5%

21.9%

 

1.8%

2.2%

 

(10%)

(11%)

 

 

 

Cold Store division

 

Cold stores, which comprise our largest business activity, saw a modest 3.3% reduction in sales (from Stg£15.1m to Stg£14.6m), a very creditable performance in a year which saw some of our end user markets, both Chinese and domestic, closed for a number of months because of the Covid 19 Pandemic.

 

Chairman's Statement (Continued)

 

 

Pallets receipted, the lifeblood of our business, were down 19%, year on year, while blast freezing volumes were down 8%, year on year. Average stock turn dis-improved from 6.6

weeks in 2019 to 7.5 weeks in 2020. Average month end occupancy for 2020 was 87%. This compares with average occupancy of 95% in 2019.

 

Against that context, divisional profits came in at a robust Stg£3m, a 9.1% decline on the Stg £3.3m in the prior year. Divisional margins stood at 20.5% in 2020, 140 basis points below the 21.9% margin outturn for 2019.

 

The year was characterised by a good if brief start, a decline through to June, with markets bottoming out in July and August before strongly recovering since then. The overall result reflects prompt and significant cost control, together with continued pricing initiatives in place around sales mix and tiered pricing.

 

Sourcing Division

 

Sales at our sourcing division declined by 2.2% in 2020, compared with the same period in 2019, from £18.2m to £17.8m. Operating profit declined by a corresponding 25%, from £0.4m to £0.3m, reflecting the trading impact of COVID-19.

 

The Group's original investment in the main Sourcing subsidiary, Townview Foods Ltd, has been fully recouped and the structures are in place to continue development of this business.

 

Dairy Division

 

Our subsidiary, Grass to Milk Company Ltd, completed a key milestone in its development; delivering its first shipment of A2 protein product to China, in the final quarter of 2020.

 

Cantwellscourt Farm Ltd's operating performance in 2020 was consistent with our expectations. Our herd, now fully converted to producing A2 milk, generated revenue 11% ahead year on year. This was driven by better production output per cow and reflective increase in milk market pricing.

 

Our farming enterprise continues to improve across key operating KPI's. Cantwellscourt Farm Ltd is providing A2 protein milk supply to Grass to Milk Ltd in the first instance.

 

 

 

 

Chairman's Statement (Continued)

 

Discontinued

 

During 2020, the group decided to discontinue ambient warehousing in Ireland. A loss in the current year of £0.07m was incurred, compared with £0.06m last year.

 

Outlook

 

I am pleased to report that the improvement in the cold store division in the later months of 2020, has continued through January and February and into March of 2021.

 

Our product sourcing division has been impacted by Covid 19 and Brexit in January & February 2021. We expect to see this to recover in the second quarter of 2021. We have identified an opportunity to develop a protein export business to South Africa, and we expect to see growth in this area during 2021.

 

We are happy with the progress made with the development of our A2 protein milk supply via Cantwellscourt Farm Ltd. Grass to Milk Company Ltd has launched its first A2 protein, using our own unique milk source. We plan to ramp up production in 2021 in conjunction with our commercial partners in the Chinese market. We will continue to execute on our strategy; continuing to develop dairy products with functional nutrition benefits, derived from our unique A2 protein grass-fed milk source.

 

Strategic Review

 

Over the course of the year, Norish received a number of expressions of interest, from third parties, for some or all of its cold stores. As a result, the board of Norish are now carrying out a strategic review in respect of all of the assets and businesses within this division.The strategic review is at an early stage and the outcome cannot be determined at this time.

 

Dividend

 

The board recommends the payment of a final dividend of 2.0 €cent per share. This will be paid on 15 October 2021 to those shareholders on the register on the 24 September 2021. It will bring the total dividend in respect of the financial year to 2.0 €cent per share, against Nil €cent per share last year.

 

On behalf of the board, I would like to thank the management team and staff for their commitment and contribution in 2020.

 

 

 

Ted O'Neill

11 March 2021

 

 

 

 

Financial Review

 

The average cold store occupancy decreased from 95% to 87%, pallets received decreased 19% and blast freezing throughput decreased 8%.

 

 

Sales

 

Total Group revenue decreased by 2% to £33.4m (2019: £34.1m). Cold store revenues decreased by 3.3% to £14.6m (2019: £15.1m). Revenues were mainly down on the lower pallets received and lower blast freezing volumes. Revenues in the sourcing division decreased by 2.2% to £17.8m (2019: £18.2m).

 

Gross profit

 

Gross profit decreased by 12% to £2.97m (2019: £3.37m).

 

Operating profit

 

Operating profit decreased by 14% to £2.29m (2019: £2.66m).

 

Finance expense (net)

 

Finance expense decreased to £0.31m (2019: £0.35m).

 

Loss from discontinued operations

 

During 2020, the group decided to discontinue the ambient warehousing in Ireland following on from the group exit in 2018 in the Juice business for the ready to drink market. A loss in the current year of £0.07m was incurred, compared to £0.06m last year.

 

Earnings per share

 

The basic adjusted earnings per share decreased by 21% to 5.02p (2019: 6.33p).

 

Capital

 

During the period we invested £2.2m (2019: £2.3m) in investing activities. £1.74m was invested in plant and equipment of which £0.36m was invested in Blast Freezers at the Wrexham store and £1.24m in other capital expenditure for the cold store division. £0.14m was invested in dairy division. We also invested £0.7m in respect of the commercialisation of our A2 protein milk business. We sold and purchased Biological assets which netted £0.2m in surplus cash.

 

Cash Position

 

Net debt decreased to £8.7m (2019: £9.7m). Cash generated from operations amounted to £3.2m (2019: £3.5m) and financing activities absorbed £0.5m (2019: £1.8m). Investment in assets was made of £2.2m (2019: £2.3m).

 

 

Financial Review (Continued)

 

Dividend

 

The board recommends the payment of a final dividend of 2.0 €cent per share. This will be paid on 15 October 2021 to those shareholders on the register on the 24 September 2021. It will bring the total dividend in respect of the financial year to 2.0 €cent per share, against Nil €cent per share last year.

Treasury policy and management

The treasury function, which is managed centrally, handles all Group funding, debt, cash, working capital and foreign exchange exposures. Group treasury policy concentrates on the minimisation of risk in all of the above areas and is overseen and approved by the Board. Speculative positions are not  taken.

 

Financial risk management

 

The Group's financial instruments comprise borrowings, cash, and various items, such as trade receivables, trade payables etc., that arise directly from its operations. The main purposes of the financial instruments not arising directly from operations is to raise finance for the Group's operations.

 

The Group may enter into derivative transactions such as interest rate swaps, caps or forward foreign currency transactions in order to minimise its risks. The purpose of such transactions is to manage the interest rate and currency risks arising from the Group's operations and its sources of finance.

 

The main risks arising from the Group's financial instruments are interest rate risk, liquidity risk, credit risk and foreign exchange risk. The Group's policies for managing each of these risks are summarised below.

 

Interest rate risk

 

The Group finances its operations through a mixture of retained profits, bank and other borrowings at both fixed and floating rates of interest and working capital. The Group determines the level of borrowings at fixed rates of interest having regard to current market rates and future trends. At the year-end there are £1.7m term loans of which £1.32m are at floating base rate plus a bank margin of 1.85% and £0.18m are at a floating rate of 3.75% and £0.2m are at Euribor plus a bank margin of 1.85%.

 

Liquidity risk

 

The Group's policy is that, in order to ensure continuity of funding, a significant portion of its borrowings should mature in more than one year. At the year-end, 76% of the Group's term loan borrowings were due to mature in more than one year. The Group achieves short-term flexibility by means of invoice finance and overdraft.

 

 

 

 

Financial Review (Continued)

 

Credit risk

 

The Group's policy is to minimise exposure to credit risk by performing the appropriate customer due diligence and monitoring the exposure to credit risk. Furthermore, for much of the Group's trading activities the Group has physical custody over customer's inventory.

 

Foreign exchange risk

 

The Group's policy is to manage foreign exchange risk which arises principally in the product sourcing division. The Group does this by mainly purchasing euros at a fixed rate forward and using this rate in establishing a selling price for its goods in order to maintain an acceptable margin.

 

 

 

 

Aidan Hughes

Finance Director

 

 

Consolidated STATEMENT OF COMPREHENSIVE INCOME

 

for the financial year ended 31 December 2020

 

 

 

 

2020

2019

 

 

 

£'000

£'000

 

 

 

 

 

Continuing operations

 

 

 

 

Revenue

 

 

33,361

34,100

Cost of sales

 

 

(30,389)

(30,733)

 

 

 

 

 

Gross profit

 

 

2,972

3,367

 

 

 

 

 

Other income

 

 

182

107

Administrative expenses

 

 

(865)

(811)

Operating profit from continuing operations

 

 

2,289

2,663

 

 

 

 

 

Finance income - interest receivable

 

 

1

1

Finance expenses - lease interest

 

 

(196)

(229)

Finance expenses - interest on bank loans

 

 

(117)

(120)

 

 

 

 

 

Profit on continuing activities before taxation

 

 

1,977

2,315

 

 

 

 

 

Income taxes - Corporation tax

 

 

(224)

(247)

Income taxes - Deferred tax

 

 

(245)

(165)

 

 

 

 

 

Profit for the financial year from continuing operations

 

 

1,508

1,903

 

 

 

 

 

Loss for the financial year from discontinued operations

 

 

(71)

(62)

 

 

 

 

 

Profit for the financial year attributable to

owners of the parent

 

 

1,437

1,841

 

 

 

 

 

Other comprehensive income

 

 

162

-

Total comprehensive income for the financial year attributable to owners of the parent

 

 

1,599

1,841

 

 

 

 

 

 

 

 

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

 

 

 

 

 

for the financial year ended 31 December 2020(continued)

 

 

 

 

 

 

 

 

2020

2019

 

 

 

 

 

Earnings per share expressed in pence per share:

 

 

 

 

From continuing operations

- basic

 

 

5.02p

6.33p

- diluted

 

 

5.02p

6.33p

 

 

 

 

 

 

 

 

 

 

From discontinued operations

- basic

 

 

(0.24)p

(0.21)p

- diluted

 

 

(0.24)p

(0.21)p

 

 

 

 

 

 

 

 

Consolidated Statement of financial position

at 31 December 2020

 

 

 

2020

2019

 

 

 

£'000

£'000

Non current assets

 

 

 

 

Goodwill

 

 

2,338

2,338

Intangible assets

 

 

1,269

564

Property, plant and equipment

 

 

22,898

22,777

Biological assets

 

 

770

824

 

 

 

27,275

26,503

Current assets

 

 

 

 

Trade and other receivables

 

 

7,526

6,857

Inventories

 

 

58

1,105

Cash and cash equivalents

 

 

1,550

1,054

Assets of disposal group classified as held for sale

 

 

381

277

 

 

 

9,515

9,293

 

 

 

 

 

TOTAL ASSETS

 

 

36,790

35,796

 

 

 

 

 

Equity attributable to owners of the parent

 

 

 

 

Share capital

 

 

5,640

5,640

Share premium account

 

 

7,321

7,321

Other reserves

 

 

141

(21)

Retained earnings

 

 

5,750

4,313

TOTAL EQUITY

 

 

18,852

17,253

 

 

 

 

 

Non-current liabilities

 

 

 

 

Borrowings

 

 

5,514

5,935

Deferred tax

 

 

1,244

1,002

 

 

 

6,758

6,937

Current liabilities

 

 

 

 

Trade and other payables

 

 

6,288

6,564

Current tax liabilities

 

 

151

231

Borrowings

 

 

4,741

4,811

 

 

 

11,180

11,606

 

 

 

 

 

TOTAL EQUITY AND LIABILITIES

 

 

36,790

35,796

 

 

 

 

 

 

 

Consolidated Statement of Changes in Equity

 

For the financial year ended 31 December 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share

Share

Other

Treasury

Retained

 

 

capital

premium

Reserves

shares

Earnings

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

At 1 January 2019

5,640

7,321

103

(563)

3,484

15,985

Profit for the financial year

 

-

-

-

 

-

1,841

1,841

 

Total comprehensive income for the financial year

-

-

-

-

1,841

1,841

Transfer of treasury shares

-

-

-

563

(563)

-

Equity dividends paid

-

-

-

-

(449)

(449)

Foreign exchange gain

-

-

(124)

-

-

(124)

 

 

 

 

 

 

 

Transactions with owners

-

-

(124)

563

(1,012)

(573)

At 31 December 2019

5,640

7,321

(21)

-

4,313

17,253

 

 

 

 

 

 

 

Profit for the financial year

-

-

-

-

1,437

1,437

Foreign exchange gain

-

-

162

-

-

162

Total comprehensive income for the financial year

-

-

162

-

1,437

1,599

Equity dividends paid

-

-

-

-

-

-

 

 

 

 

 

 

 

Transactions with owners

-

-

162

-

1,437

1,599

At 31 December 2020

5,640

7,321

141

 

-

5,750

18,852

 

 

 

Consolidated Cash Flow Statement

 for the financial year ended 31 December 2020

 

2020

2019

 

 

£'000

£'000

Cash flow from operating activities

 

 

 

Profit on continuing activities before taxation

 

1,977

2,315

Gain on biological assets

 

(182)

(107)

Foreign exchange (gain)/loss

 

(55)

97

Loss on discontinued activities

 

(71)

(62)

Finance expenses

 

316

349

Finance income

 

(1)

(1)

Depreciation - property, plant and equipment-net

 

1,789

1,649

Operating cash flows before changes in working capital

 

3,773

4,240

 

Changes in working capital and provisions:

 

 

 

Decrease/(Increase) in inventories

 

1,047

(481)

Increase in trade and other receivables

 

(669)

(607)

(Increase)/decrease in current assets held for sale

 

(104)

47

Decrease in current liabilities held for sale

 

-

(15)

(Decrease)/Increase in payables

 

(276)

1,118

Net cash inflow from operations

 

3,771

4,302

 

 

 

 

Interest paid

 

(316)

(349)

Interest received

 

1

1

Taxation paid

 

(304)

(406)

Net cash generated from operating activities

 

3,152

3,548

 

Cash flow from investing activities

 

 

 

Investment in intangible assets

 

(705)

(419)

Purchase of property, plant and equipment

 

(1,741)

(1,734)

Sale of biological assets

 

346

209

Purchase of biological assets

 

(65)

(324)

Net cash used in investing activities

 

(2,165)

(2,268)

 

Cash flows from financing activities

Dividends paid to shareholders

 

-

(449)

Invoice finance payments

 

(150)

(502)

Lease liability capital repayments

 

(845)

(979)

Term loan advance

 

-

300

Lease liability advances

 

882

271

Term loan repayments

 

(378)

(410)

Net cash outflow from financing activities

 

(491)

(1,769)

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

 

496

(489)

 

Cash and cash equivalents beginning of the financial year

 

1,054

1,543

 

 

 

 

Cash and cash equivalents end of the financial year

 

1,550

1,054

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR EAPDFFESFEFA
Date   Source Headline
22nd Nov 20216:04 pmRNSChange of Name, Board and Management Changes
22nd Nov 202110:50 amRNSResult of EGM
1st Nov 20215:00 pmRNSNotice of EGM: Amendment to RNS
29th Oct 20214:25 pmRNSNotice of EGM
29th Oct 20214:23 pmRNSCompletion of Disposal of Cold Store Division
20th Oct 202112:49 pmRNSProposed Disposal of Cold Stores
8th Oct 20218:46 amRNSResult of AGM
30th Sep 202111:05 amRNSSecond Price Monitoring Extn
30th Sep 202111:00 amRNSPrice Monitoring Extension
30th Sep 20219:30 amRNSDisposal
15th Sep 20215:13 pmRNSNotice of AGM
4th Aug 20217:00 amRNSInterim Results 2021
1st Apr 202110:15 amRNSAnnual Financial Report
12th Mar 20217:00 amRNSPreliminary Results
11th Mar 202112:10 pmRNSConfirmation of Migration
18th Feb 20214:27 pmRNSEGM Results
22nd Jan 202112:45 pmRNSNotice of EGM
24th Aug 20209:39 amRNSCorrection - Half-year Report
20th Aug 20201:10 pmRNSResult of AGM
20th Aug 202010:30 amRNSHalf-year Report
24th Jul 20204:13 pmRNSNotice of AGM
8th Apr 202012:57 pmRNSAnnual Financial Report
1st Apr 202010:47 amRNSFurther Covid-19 Update
25th Mar 202010:33 amRNSCovid-19 - AGM and Dividend Update
13th Mar 20207:00 amRNSPreliminary Results
19th Nov 20195:49 pmRNSHolding(s) in Company
7th Nov 20195:33 pmRNSDirector/PDMR Shareholding
10th Oct 20191:06 pmRNSDirector/PDMR Shareholding
20th Sep 20197:00 amRNSHalf-year Report
8th Aug 20194:11 pmRNSHolding(s) in Company
23rd May 20193:18 pmRNSResult of AGM
23rd May 20199:25 amRNSTrading update ahead of AGM
2nd May 20194:57 pmRNSHolding(s) in Company
5th Apr 201910:15 amRNSAnnual Report and Notice of AGM
8th Mar 20197:00 amRNSPreliminary Results
21st Jan 20192:09 pmRNSHolding(s) in Company
23rd Oct 20182:12 pmRNSDirector/PDMR Shareholding
21st Sep 20181:49 pmRNSDirector/PDMR Shareholding
20th Sep 20187:00 amRNSHalf-year Report
23rd May 20181:55 pmRNSResult of AGM
23rd May 20187:00 amRNSTrading update ahead of AGM
26th Apr 20187:00 amRNSExercise of options and PDMR Notification
13th Apr 20187:00 amRNSAnnual Report and Notice of AGM
3rd Apr 201811:34 amRNSCompany Secretary Appointment
28th Mar 20187:00 amRNSPreliminary results
25th Oct 20179:48 amRNSDirector/PDMR Shareholding
14th Sep 20177:00 amRNSHalf-year Report
29th Jun 20172:44 pmRNSHolding(s) in Company
10th May 201711:22 amRNSResult of AGM
10th May 20177:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.